Cohance Lifesciences Limited Fundamental Analysis (BSE: COHANCE.BO)
Cohance Lifesciences Limited Fundamental Analysis (BSE: COHANCE.BO)
Cohance Lifesciences Limited (BSE: COHANCE.BO) shows weak financial fundamentals with a PE ratio of 109.98, profit margin of 4.96%, and ROE of 2.74%. The company generates $21.4B in annual revenue with strong year-over-year growth of 13.91%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze COHANCE.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakCOHANCE.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateCOHANCE.BO shows balanced valuation metrics.
Growth Score
ModerateCOHANCE.BO shows steady but slowing expansion.
Financial Health Score
ExcellentCOHANCE.BO maintains a strong and stable balance sheet.
Profitability Score
ModerateCOHANCE.BO maintains healthy but balanced margins.
Key Financial Metrics
Is COHANCE.BO Expensive or Cheap?
P/E Ratio
COHANCE.BO trades at 109.98 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, COHANCE.BO's PEG of -1.89 indicates potential undervaluation.
Price to Book
The market values Cohance Lifesciences Limited at 4.55 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 54.95 times EBITDA. This signals the market has high growth expectations.
How Well Does COHANCE.BO Make Money?
Net Profit Margin
For every $100 in sales, Cohance Lifesciences Limited keeps $4.96 as profit after all expenses.
Operating Margin
Core operations generate 5.81 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.74 in profit for every $100 of shareholder equity.
ROA
Cohance Lifesciences Limited generates $2.05 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cohance Lifesciences Limited produces operating cash flow of $2.61B, showing steady but balanced cash generation.
Free Cash Flow
Cohance Lifesciences Limited produces free cash flow of $1.71B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $4.48 in free cash annually.
FCF Yield
COHANCE.BO converts 0.97% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
109.98
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.89
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.27
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.38
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How COHANCE.BO Stacks Against Its Sector Peers
| Metric | COHANCE.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 109.98 | 30.97 | Worse (Expensive) |
| ROE | 2.74% | 515.00% | Weak |
| Net Margin | 4.96% | 30197.00% | Weak |
| Debt/Equity | 0.05 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 5.38 | 5.71 | Strong Liquidity |
| ROA | 2.05% | -16.00% (disorted) | Weak |
COHANCE.BO outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cohance Lifesciences Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
42.61%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-16.10%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-31.22%
Industry Style: Defensive, Growth, Innovation
Declining